The stock of BIOLASE Inc. (BIOL) is trading down-7.00% to $1.4000. It has been trading 14.75% below its three-month high price recently. Another look at the chart shows it trading +395.08% above its three-month low. BIOL is trading -14.75% below its 52-week high and 548.66% above its 52-week low price based on a more comprehensive view.
For its fourth quarter ended December 31, BIOLASE, Inc. (NASDAQ: BIOL) reported unaudited preliminary revenue results. It also announced that it currently has about $25 million in cash and can execute its revenue growth strategy with that cash on hand.
Sales are expected to reach between $8.2 million and $8.6 million, representing a sequential growth rate of 26-31%. Despite COVID-19 headwinds, U.S. revenue exceeded the previous-year fourth quarter. The number of new users continued its upward trend. Over 40% of sales came from a specialist, a significant increase compared to prior periods. In the US, Waterlase iPlus’s ASPs have increased by 22% compared to the previous year. In the fourth quarter, BIOLASE technology was acquired by four different DSOs.
Company management expects to provide its final financial results for its fourth quarter and full-year 2020 in March.
Suppose we take a glance at the Ownership summary of BIOLASE Inc.’s stock. With 5.17 million shares, Oracle Investment Management, Inc. was the top institutional holder of BIOLASE Inc. (BIOL). With 2.68 million shares, Archon Capital Management LLC is the next largest fund holder of this company’s stock. Perkins Capital Management, Inc. has 1.32 million shares and is ranked third.